French Cohort for the Study of Non-invasive Tests of Liver Lesions in NAFLD/NASH (FreSH Cohort)

Inclusion Criteria

• •NAFLD diagnosis defined by the presence of at least two of the following elements:
• •* Liver steatosis (hyperechoic liver on hepatic ultrasound, quantification \> 5.6 % by spectroscopy or MRI)
• •* Presence of one metabolic risk factor:
• •* BMI ≥ 25 kg/m2 or waist circumference ≥ 94 cm (male) / ≥ 80 cm (female)
• •* Antihypertensive treatment or systolic BP ≥ 130 mmHg or diastolic BP ≥ 85 mmHg
• •* Antidiabetic treatment or fasting blood glucose ≥ 5.6 mmol/l
• •* Lipid-lowering treatment or triglycerides ≥ 1.71 mmol/l or HDL cholesterol \<1.1 mmol/l (male) / \<1.3 mmol/l (female)
• •* Dysmetabolic hyperferritinemia
• •* Anomaly in the liver enzyme test or liver function tests
• •Indication for liver biopsy in the clinical management of the patient
• •Obtaining the signature of the consent to participate in the study